Clinical Use of Therapies Targeting Tumor Vasculature and Stroma

Grants

Funding Acknowledgements

IDD is supported in part by a Victorian Cancer Agency Clinician Researcher Fellowship and is an Australian NHMRC Honorary Practitioner Fellow. IDD and JD are members of the Australian Pfizer Sutent Advisory Board. IDD is also chair of the Bayer Nexavar Advisory Board and a member of the Wyeth Torisel (RCC) Advisory Board, with all payments for his work donated to the Austin Hospital Medical Research Foundation to support research into urologic cancers. JD is also member of the Novartis GIST Advisory Board, and has received speaking honoraria from Pfizer and Novartis.